Matthew Dankner
Overview
Explore the profile of Matthew Dankner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
701
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dankner M, Rousselle E, Petrecca S, Fabi F, Nowakowski A, Lazaratos A, et al.
JCO Precis Oncol
. 2025 Jan;
9:e2400199.
PMID: 39869838
Purpose: MAP2K1/MEK1 mutations are potentially actionable drivers in cancer. MAP2K1 mutations have been functionally classified into three groups according to their dependency on upstream RAS/RAF signaling. However, the clinical efficacy...
2.
Lazaratos A, Dankner M, Hamouda A, Labidi S, Cohen V, Panasci L, et al.
Curr Oncol
. 2025 Jan;
32(1.
PMID: 39851917
Background: Trastuzumab deruxtecan (TDXd) is an antibody-drug conjugate that has demonstrated impressive activity in randomized controlled clinical trials in the context of patients with HER2-amplified and HER2-low metastatic breast cancer....
3.
Lazaratos A, Bian D, Petrecca K, Guiot M, Dankner M
Transl Lung Cancer Res
. 2025 Jan;
13(12):3824-3830.
PMID: 39830768
No abstract available.
4.
Zhu J, Shum M, Qazi M, Sahgal A, Das S, Dankner M, et al.
J Neurooncol
. 2024 Dec;
172(1):31-40.
PMID: 39704899
Purpose: To review applications of cerebral spinal fluid (CSF) biomarkers for the diagnosis, monitoring and treatment of leptomeningeal metastatic disease (LMD) among patients with metastatic solid tumors. Methods: A narrative...
5.
Najafian K, Rehany B, Nowakowski A, Ghazimoghadam S, Pierre K, Zakarian R, et al.
Neurooncol Adv
. 2024 Dec;
6(1):vdae200.
PMID: 39679176
Background: Brain metastasis invasion pattern (BMIP) is an emerging biomarker associated with recurrence-free and overall survival in patients, and differential response to therapy in preclinical models. Currently, BMIP can only...
6.
Bian D, Cohen S, Lazaratos A, Bouganim N, Dankner M
Curr Oncol
. 2024 Oct;
31(10):6314-6342.
PMID: 39451775
Antibody-drug conjugates (ADCs) represent an emerging class of targeted anticancer agents that have demonstrated impressive efficacy in numerous cancer types. In non-small cell lung cancer (NSCLC), ADCs have become a...
7.
Lazaratos A, Petrecca K, Guiot M, Jerzak K, Dankner M
Lancet Oncol
. 2024 Jun;
25(7):e282.
PMID: 38936381
No abstract available.
8.
Dankner M, Maxwell J, Rose A
Transl Lung Cancer Res
. 2024 May;
13(4):930-935.
PMID: 38736490
No abstract available.
9.
Bian D, Lazaratos A, Maritan S, Quaiattini A, Zeng Z, Zhu Z, et al.
Heliyon
. 2024 May;
10(9):e29668.
PMID: 38698967
Purpose: Leptomeningeal metastasis (LM) is a severe complication of non-small cell lung cancer (NSCLC). In patients with NSCLC LM harboring epidermal growth factor receptor () mutations, osimertinib is favored over...
10.
Sorin M, Prosty C, Ghaleb L, Nie K, Katergi K, Shahzad M, et al.
JAMA Oncol
. 2024 Mar;
10(5):621-633.
PMID: 38512301
Importance: To date, no meta-analyses have comprehensively assessed the association of neoadjuvant chemoimmunotherapy with clinical outcomes in non-small cell lung cancer (NSCLC) in randomized and nonrandomized settings. In addition, there...